LMP-400 is under clinical development by Gibson Oncology and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect LMP-400’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 19 Aug 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their LMP-400 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Indotecan (LMP-400, NSC-743400) is under development for the treatment of relapsed and refractory solid tumors, Hodgkin lymphoma, non-Hodgkin lymphoma, metastatic colorectal cancer, triple negative breast cancer with brain metastasis, pancreatic cancer, pediatric cancers including Ewing sarcoma, metastatic pheochromocytoma and neuroblastoma. It is administered by intravenous infusion. The drug candidate is an indenoisoquinoline which acts by targeting topoisomerase I (Top I). It was also under development for visceral leishmaniasis and prostate cancer.
Quick View LMP-400 LOA Data
|Highest Development Stage|